Screening of BRCA1 and BRCA2 genes and their therapeutic implications in triple-negative breast cancer: a systematic review of the literature

Conteúdo do artigo principal

Julia Barbosa Gomes
Rafael Souto

Resumo

O câncer de mama representa uma das neoplasias de maior prevalência e mortalidade entre as mulheres, exigindo intervenções estratégicas de saúde pública para mitigar seus impactos sociais e clínicos. Este trabalho tem como objetivo analisar os aspectos biológicos e epidemiológicos do câncer de mama no Brasil, destacando os mecanismos celulares envolvidos na progressão tumoral e a relevância do rastreamento precoce. Metodologia: Trata-se de uma revisão narrativa da literatura focada na regulação do ciclo celular, nas alterações da fase de síntese (fase S) e nas disparidades regionais de acesso ao diagnóstico no cenário brasileiro.Conduzida de acordo com as diretrizes PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses), as busca para esta revisão foi realizada na base de dados PubMed, resultando na seleção de 17 artigos para análise. Resultados: A literatura aponta que a progressão tumoral está intimamente associada a falhas nos pontos de checagem da replicação celular, favorecendo a proliferação desordenada de células atípicas. Sob a ótica epidemiológica, constatam-se marcantes desigualdades regionais na incidência e na mortalidade pela doença, influenciadas por fatores socioeconômicos e barreiras no acesso aos serviços de saúde. Contudo, a implantação de programas de rastreamento sistemático demonstra alta eficácia na detecção de lesões em estágios subclínicos, aumentando expressivamente as taxas de cura e permitindo abordagens terapêuticas menos invasivas. Conclusão: A compreensão integrada dos mecanismos moleculares do ciclo celular aliada a estratégias regionais assertivas de rastreamento é fundamental para reduzir a mortalidade, otimizar recursos em saúde pública e melhorar o prognóstico e a qualidade de vida das pacientes.

Detalhes do artigo

Como Citar
Barbosa Gomes, J., & Souto, R. (2026). Screening of BRCA1 and BRCA2 genes and their therapeutic implications in triple-negative breast cancer: a systematic review of the literature. Revista Brasileira De Ciências Biomédicas, 7(1), E0129202 – 1. https://doi.org/10.46675/rbcbm.v7i1.129
Seção
Artigos em fluxo contínuo
Biografia do Autor

Julia Barbosa Gomes, Biomédica (CRBM 30832) pela Pontifícia Universidade Católica de Goiás.

Biomédica (CRBM 30832) pela Pontifícia Universidade Católica de Goiás.

Rafael Souto, Professor da Pontifícia Universidade Católica de Goiás.

Doutor em Epidemiologia pela Universidade Federal de Goiás-UFG. Professor da Pontifícia Universidade Católica de Goiás. 

Referências

Zhang Y, et al. Healthy lifestyles, systemic inflammation and breast cancer risk: a mediation analysis. BMC Cancer. 2024;24(1).

Instituto Nacional de Câncer (INCA). Estimativa 2022: Incidência de Câncer no Brasil [2022 Estimate: Cancer Incidence in Brazil]. Rio de Janeiro: INCA; 2022.

Santos MO, et al. Estimativa de incidência de câncer no Brasil, 2023–2025 [Estimated cancer incidence in Brazil, 2023–2025]. Rev Bras Cancerol. 2023;69(1).

Mercadante AA, Kasi A. Genetics, cancer cell cycle phases. [S.l.]: StatPearls Publishing; 2023. Updated 2023 Aug 14. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585118/. Accessed 2025 Sep 5.

Alberts B, Johnson A, Lewis J, et al. An overview of the cell cycle. In: Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th ed. New York: Garland Science; 2002.

Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26(7):1291–1299.

Wong EV. Tumor Suppressor Genes. In: Cells: Molecules and Mechanisms. LibreTexts Publishing; 2020. Available from: https://bio.libretexts.org/Bookshelves/Cell_and_Molecular_Biology/Cells__Molecules_and_Mechanisms_(Wong)/16%3A_Viruses_Cancer_and_the_Immune_System/16.05%3A_Tumor_Suppressor_Genes.

Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. J Natl Cancer Inst. 2018;110(8):855–862.

Wang DY, Gendoo DMA, Ben-David Y, Woodgett JR, Zacksenhaus E. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. Breast Cancer Res. 2019;21(1):18.

Gene [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004– [cited 2026 Apr 14]. Available from: https://www.ncbi.nlm.nih.gov/gene/

Lips EH, et al. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat. 2013;140(1):63–71.

Lehmann BD, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021;12(1):6276.

Gupta A, et al. A non-invasive method for concurrent detection of early-stage women-specific cancers. Sci Rep. 2022;12(1):19149.

Ugioni L, et al. Impact of mammography screening on the treatment of women diagnosed with breast cancer. Mastology. 2020;30:e20200020.

Cadavid-Fernández N, et al. The role of core needle biopsy in diagnostic breast pathology. Rev Senol Patol Mamaria. 2022;35(4):155–162.

Sinha I, et al. Potential early markers for breast cancer: a proteomic approach comparing saliva and serum samples in a pilot study. Int J Mol Sci. 2023;24(4):3849.

Ye F, et al. Insights into the impacts of BRCA mutations on clinicopathology and management of early-onset triple-negative breast cancer. Front Oncol. 2021;10:590113.

Cantor SB. Revisiting the BRCA-pathway through the lens of replication gap suppression: “Gaps determine therapy response in BRCA mutant cancer.” DNA Repair (Amst). 2021;107:103199.

Sadeghi F, et al. Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays. Biol Proced Online. 2020;22(1):13.

Brianese RC, et al. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation. Breast Cancer Res Treat. 2018;167(3):803–814.

Richters L, et al. Genetic alterations, therapy response, and survival among patients with triple-negative breast cancer: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2025;8(2):e2461639.

Li RQ, et al. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer. Sci Rep. 2024;14(1).

Telli ML, et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast Cancer. 2024;31(5):886–897.

Mutai R, et al. The impact of germline BRCA pathogenic variants in locally advanced, triple-negative breast cancer treated with platinum-based neoadjuvant chemotherapy. Breast Cancer Res Treat. 2024;205(2):241–248.

Moreno M, et al. Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer. Cancer Med. 2023;12(15):16129–16141.

Samusieva A, et al. Contribution of BRCA1 5382insC mutation to triple-negative and luminal types of breast cancer in Ukraine. Breast Cancer Res Treat. 2022;195(3):453–459.

Menghi F, et al. Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. Sci Transl Med. 2022;14(652):eabo2572.

Ji G, et al. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas. J Cancer Res Clin Oncol. 2021;147(10):2935–2944.

Glodzik D, et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple-negative breast cancers. Nat Commun. 2020;11(1):3747.

Zhu X, et al. Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer. Cancer Biol Med. 2024;21(9).

Eras N, et al. Clinicopathological characteristics and BRCA1/BRCA2 pathogenic variants of patients with breast cancer. Pol J Pathol. 2024;75(1):1–7.

Muhammad N, et al. Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan. Breast Cancer Res Treat. 2023;202(2):377–387.

Mahtani R, et al. Real-world study of regional differences in patient demographics, clinical characteristics, and BRCA1/2 mutation testing in patients with HER2-negative advanced breast cancer in the United States, Europe, and Israel. Adv Ther. 2023;40(1):190–207.

Feng C, et al. Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score. Breast. 2023;69:68–77.

Guzmán-Arocho YD, et al. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2022;126(2):302–309.

Boddicker NJ, et al. Risk of late-onset breast cancer in genetically predisposed women. J Clin Oncol. [S.l.: s.n.]. Available from: https://doi.org/10.

Chavarri-Guerra Y, et al. Breast cancer associated pathogenic variants among women 61 years and older with triple-negative breast cancer. J Geriatr Oncol. 2021;12(5):749–751.